| Outcome Measures: |
Primary: Ultrasound attenuation parameter (UAP), Changes in ultrasound attenuation parameter (UAP) from baseline. Higher UAP correlates with increased severity of steatosis., 24 weeks|Liver stiffness measurement (LSM), Changes in liver stiffness measurement (LSM) from baseline. Higher LSM values correlate with advancement in the stage of liver fibrosis., 24 weeks | Secondary: Non-Alcoholic Fatty Liver Disease Fibrosis Score (NFS), Changes in Non-Alcoholic Fatty Liver Disease Fibrosis Score (NFS) from baseline. Higher NFS score suggests advanced liver fibrosis., 24 weeks|Fibrosis Index Based on 4 Factors (FIB-4 Index), Changes in FIB-4 Index from baseline. Higher FIB-4 Index correlates with increased severity of hepatic fibrosis., 24 weeks|Liver fat content, Changes in liver fat content from baseline, 24 weeks|Liver enzymes, Changes in liver enzymes from baseline, the enzymes include ALP (alkaline phosphatase), ALT (alanine transaminase), AST (aspartate aminotransferase), and GGT (gamma-glutamyl transferase)., 24 weeks|Cholestatic proteins (Chitinase 3-like protein 1, CHI3L1), Changes in CHI3L1 from baseline. Higher CHI3L1 level suggests advanced liver fibrosis., 24 weeks|Intrabdominal fat, Changes in visceral fat area from baseline, 24 weeks|Glucose level, Changes in HbA1c from baseline, 24 weeks|Body weight, Changes in body weight from baseline, 24 weeks
|
